Registry of Hospitalized Patients Treated With Fondaparinux
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00549705|
Recruitment Status : Completed
First Posted : October 26, 2007
Last Update Posted : September 17, 2009
|Condition or disease|
|Deep Vein Thrombosis Pulmonary Embolism|
The use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (VTE) and acute coronary syndrome (ACS). Concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. Fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia.
Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.
|Study Type :||Observational|
|Actual Enrollment :||220 participants|
|Official Title:||Registry of Hospitalized Patients Treated With Fondaparinux|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||June 2009|
- Venous Thromboembolism and Bleeding Events [ Time Frame: 90 Days ]
- Mortality [ Time Frame: 30 Days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00549705
|Principal Investigator:||Samuel Z Goldhaber, MD||Brigham and Women's Hospital|